INTL.TA(INTL.TA)
INTL.TA
Intelicanna Ltd specializes in the development and manufacturing of specialty and generic pharmaceuticals, focusing on cannabinoid-based therapies. The company operates primarily in Israel, leveraging its unique position in the cannabis sector to drive innovation and capture market share in a rapidly growing industry.
Intelicanna generates revenue through the sale of proprietary cannabinoid-based medications and a range of generic drugs. Its competitive advantage lies in its advanced R&D capabilities and established distribution networks within Israel, allowing it to capitalize on the growing acceptance of medical cannabis.
Regulatory changes impacting cannabis legislation in Israel
Market adoption rates of cannabinoid therapies
Competitive product launches in the specialty drug market
Partnerships or collaborations with larger pharmaceutical companies
Regulatory changes that could restrict cannabinoid product sales
Technological advancements by competitors in drug formulation
Emergence of new players in the cannabinoid space
Price competition from generic drug manufacturers
Liquidity risk due to negative cash flow from operations
Potential future capital requirements for R&D funding
moderate - The demand for healthcare products is somewhat insulated from economic cycles, but broader economic conditions can impact consumer spending on non-essential medications.
Low - As the company has no debt, rising interest rates do not affect its financing costs. However, higher rates could impact consumer spending on healthcare.
minimal - The company operates with zero debt, reducing its exposure to credit market fluctuations.
growth - Investors are likely attracted to the potential for rapid revenue growth in the cannabinoid market.
high - The stock has experienced significant volatility, with a 1-year return of -77.6% indicating high risk.